Pomerantz LLP has launched an investigation into Dr. Reddy's Laboratories Limited over potential securities fraud, following a sharp stock decline after the company reported Q1FY27 earnings per share of just $0.06.

Investigation background

The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The probe was triggered by the company's Q1FY27 earnings announcement on July 22, 2026, which revealed significant financial damage linked to its semaglutide operations.

Semaglutide provision dents Q1FY27 results

Dr. Reddy's reported earnings per share of $0.06 for Q1FY27, weighed down in part by a ₹2.4 billion provision related to out-of-specification semaglutide batches. The company's CEO Erez Israeli attributed the quarter's weak performance to multiple semaglutide-related headwinds.

The following table summarises the key financial and market impact disclosed on July 22, 2026:

CEO Erez Israeli stated: "The quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs."

Market reaction

On July 22, 2026, Dr. Reddy's stock fell $1.18 per share, or 9.4%, closing at $11.38 per share. The semaglutide-related challenges cited by management included lower sales, provisions for rejected batches, loss of production-linked incentives, and other associated costs.

About Pomerantz LLP

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, focuses on corporate, securities, and antitrust class litigation. The firm was founded by the late Abraham L. Pomerantz and has operated for more than 85 years. Investors seeking information may contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Dr. Reddy's Laboratories (NYSE: RDY) is now under investigation by five US plaintiffs' law firms for potential violations of federal securities laws. The expanded legal scrutiny follows the company's Q1FY27 earnings miss, driven by a ₹2.4 billion provision linked to quality issues with its semaglutide product.

Investigation Details

The probes were triggered on July 22, 2026, when Dr. Reddy's disclosed financial results that fell short of expectations. Central to the negative market reaction was the ₹2.4 billion provision set aside for out-of-specification semaglutide batches.

The firm is now being investigated by Kirby McInerney LLP, The Law Offices of Frank R. Cruz, the Law Offices of Howard G. Smith, Glancy Prongay Wolke & Rotter LLP, and the newly announced Pomerantz LLP. While no lawsuit has been filed at this stage, all five firms are actively seeking information from investors who purchased or acquired Dr. Reddy's securities during the relevant period.

Despite the provision, Chief Executive Officer Erez Israeli stated there was "no impact on the product’s existing global regulatory filings" and confirmed "no patient-safety impact associated with product already supplied to the market." However, he acknowledged that the quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, the provision for rejected batches, loss of production-linked incentives, and other associated costs.

Market Reaction

The market response to the earnings disclosure was immediate and sharp. On July 22, 2026, the price of Dr. Reddy's American Depositary Shares (ADSs) fell $1.18 per share, representing a 9.4% decline. The stock closed at $11.38 on that date. The earnings per share for the quarter were reported at only $0.06.

What the Numbers Show

The divergence between management's assurance of zero regulatory or patient-safety impact and the magnitude of the ₹2.4 billion provision highlights a significant disconnect in market perception. While the company framed the issue as contained, the substantial financial hit combined with an earnings miss was sufficient to drive a single-day valuation loss of nearly one-tenth of the stock's value, indicating investor concern over potential future liabilities or reputational damage beyond the immediate batch issue.

Next Steps

Investors interested in discussing their rights regarding these matters are encouraged to contact any of the five law firms.

• Kirby McInerney LLP: Contact Lauren Molinaro for inquiries related to that investigation.
• The Law Offices of Frank R. Cruz: Contact Frank R. Cruz at 310-914-5007 or via email at info@frankcruzlaw.com .
• Law Offices of Howard G. Smith: Contact Howard G. Smith at (215) 638-4847 or via email at howardsmith@howardsmithlaw.com . The firm is located at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020.
• Glancy Prongay Wolke & Rotter LLP: Contact Charles Linehan at 310-201-9150 (Toll-Free: 888-773-9224) or via email at shareholders@glancylaw.com . The firm is located at 1925 Century Park East, Suite 2100, Los Angeles, California 90067.
• Pomerantz LLP: Contact Danielle Peyton at 646-581-9980, ext. 7980 or via email at newaction@pomlaw.com .

No further legal action has been initiated, and all investigations remain ongoing to determine if claims can be brought under federal securities laws.